Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited)

v3.24.3
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)
Series A Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2022   $ 0 $ 76,369,940 $ (75,734,927) $ 635,013
Beginning balance, shares at Dec. 31, 2022   136      
Issuance of common stock for exercise of stock options and vesting of restricted stock units   25,000 25,000
Issuance of common stock for exercise of stock options and vesting of restricted stock units, shares   1      
Issuance of common stock for public offering, net of issuance costs of $629,900   4,570,100 4,570,100
Issuance of common stock for public offering, net of issuance costs, shares   42      
Stock-based compensation   2,223,356 2,223,356
Stock-based compensation, shares   1      
Reclassification of derivative liabilities to equity   13,262,055 13,262,055
Net loss   (41,655,559) (41,655,559)
Ending balance, value at Sep. 30, 2023   $ 0 96,450,451 (117,390,486) (20,940,036)
Ending balance, shares at Sep. 30, 2023   180      
Beginning balance, value at Dec. 31, 2023 $ 0 $ 0 101,175,117 (120,806,138) (19,631,021)
Beginning balance, shares at Dec. 31, 2023 0 1,291      
Issuance of common stock for exercise of pre-funded warrants $ 2 (2)
Issuance of common stock for exercise of pre-funded warrants, shares   226,343      
Issuance of common stock for exercise of Series A warrants 17,352,653 17,352,653
Issuance of common stock for exercise of Series A warrants, shares   17,325      
Proceeds received for exercise of buydown warrants 3,500 3,500
Proceeds received for exercise of buydown warrants, shares   10      
Common stock issued for conversion of convertible notes 7,395,907 7,395,907
Common stock issued for conversion of convertible notes, shares   4,971      
Conversion of Convertible Notes 24,716,118 24,716,118
Conversion of Convertible Notes, shares 24,698        
Conversion of Preferred Stock for common stock $ 3 (3)
Conversion of preferred stock for common stock, shares (24,698) 279,043      
Issuance of common stock for exercise of Series B Warrants 1 1
Issuance of common stock for exercise of Series B Warrants, shares   14,701      
Reclassification of warrant liability to equity 3,405,662 3,405,662
Proceeds received for Issuance of warrants with May 2024 Notes, net of issuance costs of $111,194 1,023,200 1,023,200
Issuance of common stock and pre-funded warrants, net of issuance costs of $1,210,753 $ 1 10,789,260 10,789,261
Issuance of common stock and pre-funded warrants, net of issuance costs, shares   102,605      
Stock-based compensation 295,882 295,882
Common stock issued for reverse stock split due to rounding
Common stock issued for reverse stock split due to rounding, shares   11,441      
Net loss (40,292,940) (40,292,940)
Ending balance, value at Sep. 30, 2024 $ 0 $ 6 $ 166,157,295 $ (161,099,078) $ 5,058,223
Ending balance, shares at Sep. 30, 2024 0 657,730